SEK 2.76
(-8.0%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 0.02 SEK | 105.2% |
2022 | -0.45 SEK | 6.25% |
2021 | -0.48 SEK | -84.62% |
2020 | -0.26 SEK | 21.21% |
2019 | -0.33 SEK | -37.5% |
2018 | -0.24 SEK | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2023 Q4 | -0.08 SEK | -193.08% |
2023 Q3 | 0.09 SEK | 37.14% |
2023 Q1 | -0.09 SEK | 44.24% |
2023 FY | - SEK | 105.2% |
2023 Q2 | 0.06 SEK | 165.61% |
2022 FY | - SEK | 6.25% |
2022 Q4 | -0.17 SEK | -174.19% |
2022 Q3 | -0.06 SEK | 43.64% |
2022 Q2 | -0.11 SEK | 0.0% |
2022 Q1 | -0.11 SEK | 31.25% |
2021 Q1 | -0.08 SEK | 0.0% |
2021 FY | - SEK | -84.62% |
2021 Q4 | -0.16 SEK | -6.67% |
2021 Q3 | -0.15 SEK | 0.0% |
2020 FY | - SEK | 21.21% |
2019 FY | - SEK | -37.5% |
2018 FY | - SEK | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
AcuCort AB | -0.16 SEK | 114.625% |
AlzeCure Pharma AB (publ) | -0.60 SEK | 103.9% |
BioGaia AB (publ) | 3.62 SEK | 99.354% |
Enzymatica AB (publ) | -0.28 SEK | 108.357% |
Enorama Pharma AB (publ) | -1.61 SEK | 101.453% |
Gabather AB (publ) | -0.65 SEK | 103.6% |
Klaria Pharma Holding AB (publ.) | -0.36 SEK | 106.5% |
Moberg Pharma AB (publ) | -1.33 SEK | 101.759% |
Nanexa AB (publ) | -1.09 SEK | 102.147% |
Newbury Pharmaceuticals AB (publ) | -0.72 SEK | 103.25% |
Orexo AB (publ) | -3.73 SEK | 100.627% |
Probi AB (publ) | 1.48 SEK | 98.419% |
Swedencare AB (publ) | 0.37 SEK | 93.676% |
Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 99.687% |
Toleranzia AB | -0.06 SEK | 141.786% |
Vivesto AB | -0.74 SEK | 103.162% |